Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950135-08-000997
Filing Date
2008-02-14
Accepted
2008-02-14 14:40:12
Documents
1
Group Members
PETER KOLCHINSKYRA CAPITAL BIOTECH FUND II, L.P.RA CAPITAL BIOTECH FUND, L.P.RICHARD H. ALDRICH

Document Format Files

Seq Description Document Type Size
1 CHELSEA THERAPEUTICS INTERNATIONAL, LTD. (RA CAPITAL MANAGEMENT, LLC) SC 13G/A b68591ctsc13gza.htm SC 13G/A 87513
  Complete submission text file 0000950135-08-000997.txt   89641
Mailing Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277
Business Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277 704-341-1516
Chelsea Therapeutics International, Ltd. (Subject) CIK: 0001333763 (see all company filings)

EIN.: 203174202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-81457 | Film No.: 08613656
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 111 HUNTINGTON AVE, SUITE 610 BOSTON MA 02199
Business Address 111 HUNTINGTON AVE, SUITE 610 BOSTON MA 02199 617-778-2512
RA CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A